Dynavax Technologies’ (DVAX) Market Perform Rating Reaffirmed at William Blair

William Blair reiterated their market perform rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a research note released on Wednesday,Benzinga reports.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Price Performance

DVAX opened at $15.39 on Wednesday. Dynavax Technologies has a 1 year low of $9.20 and a 1 year high of $15.49. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -41.59 and a beta of 0.89. The firm’s fifty day moving average price is $10.88 and its two-hundred day moving average price is $10.51.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. The company had revenue of $94.88 million for the quarter, compared to analyst estimates of $94.00 million. As a group, analysts anticipate that Dynavax Technologies will post 0.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DVAX. Capital Fund Management S.A. purchased a new stake in Dynavax Technologies in the second quarter worth $1,669,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Dynavax Technologies during the 1st quarter worth $2,477,000. Hudson Bay Capital Management LP increased its holdings in Dynavax Technologies by 46.4% in the 2nd quarter. Hudson Bay Capital Management LP now owns 541,600 shares of the biopharmaceutical company’s stock worth $5,373,000 after acquiring an additional 171,700 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Dynavax Technologies by 222.3% in the 2nd quarter. Squarepoint Ops LLC now owns 435,577 shares of the biopharmaceutical company’s stock worth $4,321,000 after acquiring an additional 300,421 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Dynavax Technologies by 28.7% in the 2nd quarter. American Century Companies Inc. now owns 375,716 shares of the biopharmaceutical company’s stock valued at $3,727,000 after acquiring an additional 83,833 shares during the period. 96.96% of the stock is owned by institutional investors.

More Dynavax Technologies News

Here are the key news stories impacting Dynavax Technologies this week:

• Positive Sentiment: Sanofi agreed to buy Dynavax for roughly $2.2B, offering $15.50 per share in cash (about a 39% premium). The deal is the direct catalyst for the share rally because it sets a clear near‑term value for DVAX stock. Reuters
• Positive Sentiment: Company press release: Sanofi’s purchase adds Dynavax’s marketed adult Hepatitis B vaccine (HEPLISAV‑B) and a Phase 1/2 shingles candidate to Sanofi’s immunization pipeline — strategic rationale that supports deal logic. PR Newswire
• Positive Sentiment: Multiple market writeups and trade coverage highlight the buyout premium and deal buzz as the driver for the premarket and intraday surge, reinforcing investor interest and momentum. Fool
• Neutral Sentiment: Analysts: William Blair reaffirmed a “market perform” rating on DVAX — a reminder that some firms view upside as tied to deal completion rather than long‑term standalone fundamentals. Benzinga
• Neutral Sentiment: Short interest report in the feed is anomalous (shows zero / NaN); based on heavy volume today, short interest dynamics could change but current published figures appear unreliable. (No external link.)
• Negative Sentiment: Shareholder litigation risk: at least two investor‑rights firms have launched investigations about whether the $15.50 cash price is fair to Dynavax shareholders, which could lead to lawsuits, delay or pressure for a higher offer. This introduces execution risk for the deal and potential legal costs. Business Wire Ademi PR

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.